Schizophrenia and Oxidative Stress: Glutamate Cysteine Ligase Modifier as a Susceptibility Gene
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Oxidative stress could be involved in the pathophysiology of schizophrenia, a major psychiatric disorder. Glutathione (GSH), a redox regulator, is decreased in patients' cerebrospinal fluid and prefrontal cortex. The gene of the key GSH-synthesizing enzyme, glutamate cysteine ligase modifier (GCLM) subunit, is strongly associated with schizophrenia in two case-control studies and in one family study. GCLM gene expression is decreased in patients' fibroblasts. Thus, GSH metabolism dysfunction is proposed as one of the vulnerability factors for schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“several divergent genetic (e.g. Gclc, Gclm, Disc1, PRODH, G72, NRG1) (9–17) or external factors (e.g. stress, social isolation, ketamine, neonatal ventral hippocampal lesion) (18–24) collectively lead to redox dysregulation.”
From Prolonged Period of Cortical Plasticity upon Redox Dysregulation in Fast-Spiking Interneurons (2015) · cites this paper as [10]
In the citing paper
“Genetic analysis of single nucleotide polymorphisms in schizophrenia patients demonstrates mutations in the gene encoding GCL, an enzyme that is important for the production of the cellular antioxidant GSH (Tosic et al., 2006).”
From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Tosic et al., 2006
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Diagnostic and Statistical Manual of Mental Disorders
(2010) · Handbook of Disease Burdens and Quality of Life Measures · doi:10.1007/978-0-387-78665-0_5485 · Cited by 10,169
Meister, A., & Anderson, M. E. (1983) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.52.070183.003431 · Cited by 5,680
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Cortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297 · cited 1×
“Gheorghita, unpublished data) and, selectively, in GABAparvalbumin immunoreactivity of prefrontal cortex,(21) similar to patients.(38,39) The same rat model presented an impairment in object recognition(18,19) and in integration ofolfactory information,(40) reproducingsomecognitivedeficits of schizophrenia.”
BackgroundDiagnostic Interview for Genetic Studies: Rationale, Unique Features, and Training
Nurnberger, J. I. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950110009002 · Cited by 2,053
NMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020
Prabakaran, S., Swatton, J. E., Ryan, M. M., Huffaker, S. J., Huang, J.-J., Griffin, J. L., Wayland, M., Freeman, T., Dudbridge, F., Lilley, K. S., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001511 · Cited by 971
Schizophrenia: genes and environment
Tsuang, M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00289-9 · Cited by 597
Genes for schizophrenia? Recent findings and their pathophysiological implications
Harrison, P. J., & Owen, M. J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12379-3 · Cited by 597
Research works printed but not linked: 1
- Cabungcal, 2004, Special bias deficit in rats with low glutathione during development: a behaviour model with relevance to schizophrenia, Schizophr Res, 67, 118
Cited by
Items 101–200 of 225
Assessing oxidative pathway genes as risk factors for bipolar disorder
Fullerton, J. M., Tiwari, Y., Agahi, G., Heath, A., Berk, M., Mitchell, P. B., & Schofield, P. R. (2010) · Bipolar Disorders · doi:10.1111/j.1399-5618.2010.00834.x · Cited by 37
Human dermal fibroblasts in psychiatry research
Kalman, J. L., Garbett, K. A., Janka, Z., & Mirnics, K. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.01.067 · Cited by 48
“…main antioxidant mechanism across various tissues (Meister, 1995), 2) genetic variants of the GCLM-subunit appear to be associated with greater risk to SZ (Tosic et al., 2006), and 3) in vivo and postmortem studies reported decreased GSH levels in the SZ brain (Yao et al., 2006; Do et al, 2000).”
BackgroundMethodInfluentialSmesny, S., Milleit, B., Schaefer, M. R., Hipler, U.-C., Milleit, C., Wiegand, C., Hesse, J., Klier, C. M., Holub, M., Holzer, I., et al. (2015) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2015.07.001 · Cited by 36
“Alternatively, the finding of weak GSHt reduction by PUFA-E is also compatible with the fact that oxidative stress induces GSH synthesis as an adaptive response which is obviously deficient in schizophrenic patients [32,37].”
BackgroundAndreazza, A. C. (2012) · Molecular BioSystems · doi:10.1039/c2mb25118c · Cited by 42
Erythrocyte glutathione levels as long-term predictor of transition to psychosis
Lavoie, S., Berger, M., Schlögelhofer, M., Schäfer, M. R., Rice, S., Kim, S.-W., Hesse, J., McGorry, P. D., Smesny, S., & Amminger, G. P. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.30 · Cited by 35
Górny, M., Bilska‐Wilkosz, A., Iciek, M., Hereta, M., Kamińska, K., Kamińska, A., Chwatko, G., Rogóż, Z., & Lorenc‐Koci, E. (2020) · Antioxidants · doi:10.3390/antiox9060538 · Cited by 37
Currently recognized genes for schizophrenia: High‐resolution chromosome ideogram representation
Butler, M. G., McGuire, A., Masoud, H., & Manzardo, A. M. (2015) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32391 · Cited by 37
Smesny, S., Klemm, S., Stockebrand, M., Grunwald, S., Gerhard, U.-J., Rosburg, T., Sauer, H., & Blanz, B. (2007) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2007.08.006 · Cited by 35
Monte, A. S., da Silva, F. E. R., Lima, C. N. D. C., Vasconcelos, G. S., Gomes, N. S., Miyajima, F., Vasconcelos, S. M. M., Gama, C. S., Seeman, M. V., de Lucena, D. F., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119875979 · Cited by 39
“Genetic polymorphisms of the GSH pathway, including the glutamate–cysteine ligase gene have been reported in schizophrenia (Tosic et al., 2006), as well as decreases in GSH in cerebrospinal fluid and in the PFC as seen by magnetic resonance spectroscopy (MRS) and in post-mortem studies (Gawryluk et…”
BackgroundMethodHasam‐Henderson, L. A., Gotti, G. C., Mishto, M., Klisch, C., Gerevich, Z., Geiger, J. R. P., & Kovács, R. (2018) · Scientific Reports · doi:10.1038/s41598-018-27830-2 · Cited by 37
Discovery and development of integrative biological markers for schizophrenia
Oertel‐Knöchel, V., Bittner, R. A., Knöchel, C., Prvulovic, D., & Hampel, H. J. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.05.006 · Cited by 36
“An association between schizophrenia and a number of polymorphisms in the gene coding for the key glutathione synthesizing enzyme glutamate cystein ligase has recently been demonstrated (Gysin et al., 2007; Tosic et al., 2006).”
Seredenina, T. S., Sorce, S., Herrmann, F. R., Mulone, X.-J. M., Plastre, O., Aguzzi, A., Jaquet, V., & Krause, K.-H. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.175 · Cited by 35
Michel, T. M., Sheldrick, A. J., Camara, S., Grünblatt, E., Schneider, F., & Riederer, P. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.526146 · Cited by 30
“…in schizophrenia both in peripheral blood as well as in brain tissue (Herken et al. 2001; Ranjekar et al. 2003; Zhang et al. 2003, 2009; Michel et al. 2004; Yao et al. 2004; Akyol et al. 2005; Preisig and Saraga 2006; Yao et al. 2006; Matsuzawa et al. 2008; Othmen et al. 2008; Virit et al. 2009).”
BackgroundOxidative/Nitrosative Stress in Psychiatric Disorders: Are We There Yet?
O’Donnell, P., Do, K. Q., & Arango, C. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu048 · Cited by 31
Early onset senescence occurs when fibroblasts lack the glutamate–cysteine ligase modifier subunit
Chen, Y., Johansson, E., Fan, Y., Shertzer, H. G., Vasiliou, V., Nebert, D. W., & Dalton, T. P. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.05.003 · Cited by 28
“In addition, SNPs in GCLM have been associated with the development of schizophrenia [44].”
BackgroundLangbein, K., Hesse, J., Gussew, A., Milleit, B., Lavoie, S., Amminger, G. P., Gaser, C., Wagner, G., Reichenbach, J. R., Hipler, U. ‐., et al. (2017) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2017.10.005 · Cited by 31
Samuelsson, M., Skogh, E., Lundberg, K., Vrethem, M., & Öllinger, K. M. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.09.014 · Cited by 28
“GSH-related enzymes and schizophrenia (Tosic et al., 2006; Gysin et al., 2007; Gravina et al., 2011; Nafissi et al., 2011).”
Cole, T. B., Giordano, G., Co, A. L., Mohar, I., Kavanagh, T. J., & Costa, L. G. (2011) · Journal of Toxicology · doi:10.1155/2011/157687 · Cited by 29
Systemic Neurochemical Alterations in Schizophrenic Brain: Glutamate Metabolism in Focus
Burbaeva, G. S., Бокша, И. С., Терешкина, Е. Б., Savushkina, O. K., Starodubtseva, L. I., Turishcheva, M. S., & Mukaetova-Ladinska, E. B. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9328-7 · Cited by 27
Adla, S. K., Virtanen, H., Thongsodsaeng, T., & Huttunen, K. M. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105771 · Cited by 27
“Moreover, polymorphism in glutamate-cysteine ligase has also been interlinked with schizophrenia (Tosic et al., 2006) and the studies examining have revealed that schizophrenia patients ’ CSF, striatum post-mortem tissues, and prefrontal cortex in vivo tissues display decreased GSH levels (Yao et…”
No evidence that major mtDNA European haplogroups confer risk to schizophrenia
Mosquera‐Miguel, A., Torrell-Galceran, H., Abasolo-Zabalo, N., Arrojo, M., Paz, E., Ramos‐Ríos, R., Agra, S., Páramo, M., Brenlla, J., Martínez, S., et al. (2012) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32044 · Cited by 28
“Expression of key genes involved in GSH synthesis is reduced in cultured fibroblasts of SZ in comparison to controls, and they present polymorphisms associated to SZ in European samples [Tosic et al., 2006; Gysin et al., 2007], although these results are pending confirmation.”
ResultPPARα Signaling: A Candidate Target in Psychiatric Disorder Management
Scheggi, S., Pinna, G., Braccagni, G., Montis, M. G. D., & Gambarana, C. (2022) · Biomolecules · doi:10.3390/biom12050723 · Cited by 28
“Genetic studies have shown associations between allelic variations in genes codifying enzymes involved in glutathione biosynthesis/metabolism and schizophrenia [128,129].”
BackgroundWang, L., Lin, P., Lee, Y., Huang, Y., Wu, C., Hsu, S., Chen, C.-C., Chong, M., Lin, C., & Hung, C. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.03.041 · Cited by 27
“…ligase modifier (GCLM) subunit, has been associated with schizophrenia in several Caucasian studies (Gysin et al., 2011; Gysin et al., 2007; Tosic et al., 2006); however, such a correlation was not replicated in the Japanese population (Hanzawa et al., 2011; Kishi et al., 2008) or in the…”
BackgroundSteullet, P., Lavoie, S., Kraftsik, R., Guidi, R., Gysin, R., Cuénod, M., & Kim, Q. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.12.006 · Cited by 28
Self-citationMeta-analyses of 10 polymorphisms associated with the risk of schizophrenia
Dai, D., Wang, Y., Yuan, J., Zhou, X., Jiang, D., Li, J., Zhang, Y., Yin, H., & Duan, S. (2014) · Biomedical Reports · doi:10.3892/br.2014.308 · Cited by 28
“GCLM encodes glutamate-cysteine ligase modifier (GCLM), which is a key enzyme of the GSH pathway that may be associated with SCZ (35).”
Górny, M., Wnuk, A., Kamińska, A., Kamińska, K., Chwatko, G., Bilska‐Wilkosz, A., Iciek, M., Kajta, M., Rogóż, Z., & Lorenc‐Koci, E. (2019) · Molecules · doi:10.3390/molecules24234253 · Cited by 26
Engström, K. S., Wennberg, M., Strömberg, U., Bergdahl, I. A., Hallmans, G., Jansson, J., Lundh, T., Norberg, M., Rentschler, G., Vessby, B. O., et al. (2011) · Environmental Health · doi:10.1186/1476-069x-10-33 · Cited by 25
“The allele frequencies reported here were similar to another study, analyzing Danish and Swiss populations, where Hardy-Weinberg equilibrium was reported [ 27 ].”
ResultMaternal serum docosahexaenoic acid and schizophrenia spectrum disorders in adult offspring
Harper, K. N., Hibbeln, J. R., Deckelbaum, R., Quesenberry, C. P., Schaefer, C. A., & Brown, A. S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.01.009 · Cited by 22
“Some studies in humans suggest that high levels of DHA can result in increased oxidative damage (Calzada et al., 2010; Guillot et al., 2009), which in turn has been linked to increased risk for SSD (Gysin et al. 2007; Prabakaran et al., 2004; Tosic et al., 2006).”
BackgroundLavoie, S., Allaman, I., Petit, J.-M., Kim, Q., & Magistretti, P. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022875 · Cited by 26
“limiting enzyme in the synthesis of GSH, is associated with schizophrenia [20].”
BackgroundGenetic variants in glutamate cysteine ligase confer protection against type 2 diabetes
Azarova, I. E., Klyosova, E. Y., Lazarenko, V. A., Konoplya, A. I., & Polonikov, A. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05647-5 · Cited by 23
Redox Dysregulation in Schizophrenia: Genetic Susceptibility and Pathophysiological Mechanisms
Do, K. Q., Bovet, P., Cabungcal, J.-H., Conus, P., Gysin, R., Lavoie, S., Steullet, P., & Cuénod, M. (2009) · Springer eBooks · doi:10.1007/978-0-387-30410-6_8 · Cited by 25
Self-citationNeuroprotection in Schizophrenia and Its Therapeutic Implications
Kim, Y., & Na, K. (2017) · Psychiatry Investigation · doi:10.4306/pi.2017.14.4.383 · Cited by 25
Effect of ketamine on oxidative stress following lipopolysaccharide administration
Abdel‐Salam, O. M. E., Youness, E. R., Mohammed, N. A., Omara, E. A. A., & Sleem, A. A. (2013) · Comparative Clinical Pathology · doi:10.1007/s00580-013-1854-x · Cited by 21
“…there is an evidence of decreased glutathione in cortex, striatum and cerebrospinal fluid (Do et al. 2004; Yao andReddy 2011) and decreased expression of the gene of the key GSH-synthesizing enzyme, glutamate cysteine ligase modifier subunit in patients' fibroblasts (Tosic et al. 2006).”
BackgroundGlutathione deficient C57BL/6J mice are not sensitized to ozone-induced lung injury
Johansson, E., Wesselkamper, S. C., Shertzer, H. G., Leikauf, G. D., Dalton, T. P., & Chen, Y. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.04.105 · Cited by 25
“Furthermore, studies in human populations have shown that polymorphisms in the GCLM gene are associated with increased risks for myocardial infarction, schizophrenia, and body burden of methyl mercury, which demonstrates that fairly modest reductions in GSH synthesis can have profound health implications [11–13].”
BackgroundAssociation study of MiRSNPs with schizophrenia, tardive dyskinesia and cognition
John, J., Bhatia, T., Kukshal, P., Chandna, P., Nimgaonkar, V. L., Deshpande, S. N., & Thelma, B. K. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.03.031 · Cited by 22
“On the other hand, GCLM codes for the first rate-limiting enzyme in glutathione synthesis and its decreased expression in SZ patient fibroblasts (Tosic et al., 2006) and in peripheral blood of SZ patients (Che et al.”
BackgroundGysin, R., Riederer, I. M., Cuénod, M., Kim, Q., & Riederer, B. M. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2008.10.015 · Cited by 20
Self-citationIs it time to reassess alpha lipoic acid and niacinamide therapy in schizophrenia?
Seybolt, S. E. J. (2010) · Medical Hypotheses · doi:10.1016/j.mehy.2010.07.034 · Cited by 19
“tibility gene [54].”
Pejovic-Milovancevic, M. M., Mandić-Maravić, V., Coric, V. M., Mitković-Vončina, M., Kostic, M. V., Savic-Radojevic, A. R., Ercegovac, M., Matic, M. G., Peljto, A., Lečić‐Toševski, D., et al. (2016) · Laboratory Medicine · doi:10.1093/labmed/lmw017 · Cited by 20
Schmidt, S. J., Hurlemann, R., Schultz, J., Wasserthal, S., Kloss, C., Maier, W., Meyer‐Lindenberg, A., Hellmich, M., Muthesius, A., Pantel, T., et al. (2019) · Early Intervention in Psychiatry · doi:10.1111/eip.12781 · Cited by 19
“Polymorphisms of genes involved in GSH synthesis, leading to suppressed protein expression and reduced GSH levels, have also been associated with an enhanced risk for schizophrenia (Gysin et al., 2007; Tosic et al., 2006).”
BackgroundJanickova, L., & Schwaller, B. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.571216 · Cited by 22
“, 2016), and adult schizophrenia patients (Tosic et al., 2006) might be implicated in ASD and schizophrenia etiology.”
BackgroundGüler, E. M., Kurtulmuş, A., Gül, A. Z., Koçyiğit, A., & Kırpınar, İ. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14711 · Cited by 18
Exploring the role of ketone bodies in the diagnosis and treatment of psychiatric disorders
Omori, N. E., Malys, M. K., Woo, G. H., & Mansor, L. S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1142682 · Cited by 21
Analysis of differential gene expression mediated by clozapine in human postmortem brains
Lee, B. J., Marchionni, L., Andrews, C. E., Norris, A. L., Nucifora, L. G., Wu, Y. C., Wright, R. A., Pevsner, J., Ross, C. A., Margolis, R. L., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.12.017 · Cited by 19
“Furthermore, polymorphisms in GCLM specifically have been associated with schizophrenia in human casecontrol studies (Tosic et al., 2006), while knockout mouse models of GCLM show elevated oxidative stress in the brain and a behavioral phenotype relevant to schizophrenia (Steullet et al., 2016).”
BackgroundLech, M. A., Leśkiewicz, M., Kamińska, K., Rogóż, Z., & Lorenc‐Koci, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126171 · Cited by 23
Jeon, P., Limongi, R., Ford, S. D., Branco, C., Mackinley, M., Gupta, M., Powe, L., Théberge, J., & Palaniyappan, L. K. (2021) · Brain Sciences · doi:10.3390/brainsci11070941 · Cited by 17
Kishi, T., Ikeda, M., Kitajima, T., Yamanouchi, Y., Kinoshita, Y., Kawashima, K., Inada, T., Harano, M., Komiyama, T., Hori, T., et al. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1432.022 · Cited by 19
Schizophrenia and Glutathione: A Challenging Story
Carletti, B., Banaj, N., Piras, F., & Bossù, P. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13111526 · Cited by 22
Corcoba, A., Gruetter, R., Kim, Q., & Duarte, J. M. N. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14116 · Cited by 18
“(2017) 142, 767--775 767 schizophrenia (Tosic et al. 2006; Gysin et al. 2007, 2011).”
Oxidative stress and dysregulated Nrf2 activation in the pathogenesis of schizophrenia
Genç, K., & Genç, Ş. (2008) · Bioscience hypotheses · doi:10.1016/j.bihy.2008.10.005 · Cited by 17
Effect of chronic glutathione deficiency on the behavioral phenotype of Gclm(−/−) knockout mice
Chen, Y., Curran, C. P., Nebert, D. W., Patel, K. V., Williams, M. T., & Vorhees, C. V. (2012) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2012.04.009 · Cited by 18
“This pathology is consistent with our behavioral phenotype, because it would not affect spatial learning and memory, but could produce behaviors associated with the onset of schizophrenia which has been linked to reduced GSH in humans (Tosic et al., 2006).”
BackgroundHashimoto, T., Hashimoto, K., Miyatake, R., Matsuzawa, D., Sekine, Y., Inada, T., Ozaki, N., Iwata, N., Harano, M., Komiyama, T., et al. (2008) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30703 · Cited by 17
“The SNP ( 588C/T) in the promoter region of the GCLM gene was associated with higher promoter activity [Nakamura et al., 2002], and an SNP (G>A, rs2301022) in the intron was demonstrated to be associated with the pathogenesis of schizophrenia [Tosic et al., 2006].”
BackgroundThe Role of Glutathione in the Management of Cell-Mediated Immune Responses in Individuals with HIV
Lin, N., Erdos, T., Louie, C., Desai, R., Lin, N., Ayzenberg, G., & Venketaraman, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052952 · Cited by 22
“Mutations in either of these subunits are points of polymorphisms seen at least in schizophrenia [24], stroke [25], diabetes [26], asthma [27], MI [28], and coronary artery disease [29].”
BackgroundCystamine induces AIF-mediated apoptosis through glutathione depletion
Cho, S., Lee, J.-H., Ju, M.-K., Jeong, E. M., Kim, H.-J., Lim, J., Lee, S., Cho, N., Park, H. H., Choi, K., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.12.028 · Cited by 16
“At the enzyme level, GCSC activity is increased by GCSM in response to oxidative insults, but is inhibited by GSH via negative feedback [44].”
BackgroundGenetic analysis of glutamate cysteine ligase modifier (GCLM) gene and schizophrenia in Han Chinese
Ma, J., Li, D., Zhang, R., Yang, X., Gao, C., Lu, S., Wu, S., & Wang, L. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.12.017 · Cited by 15
No association between glutathione‐synthesis‐related genes and Japanese schizophrenia
Hanzawa, R., Ohnuma, T., Nagai, Y., Shibata, N., Maeshima, H., Baba, H., Hatano, T., Takebayashi, Y., Hotta, Y., Kitazawa, M., et al. (2010) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2010.02157.x · Cited by 14
“For GCLC, trinucleotide repeat (TNR) polymorphisms situated at the 5′-untranslated region of GCLC showed significant associations with European patients with schizophrenia,(23) whereas GSS did not.(19) However, to the best of our knowledge, the latter two genes have not been investigated in the Japanese population.”
BackgroundReyes-Madrigal, F., León-Ortíz, P., Mao, X., Mora-Durán, R., Shungu, D. C., & de la Fuente‐Sandoval, C. (2019) · Archives of Medical Research · doi:10.1016/j.arcmed.2019.08.003 · Cited by 14
Adraoui, F. W., Douw, L., Martens, G. J. M., & Maas, D. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097680 · Cited by 31
Butticaz, C., Werge, T. M., Beckmann, J. S., Cuénod, M., Kim, Q., & Rivolta, C. (2009) · Psychiatric Genetics · doi:10.1097/ypg.0b013e32832cef21 · Cited by 14
“The notion that GCLM variability might be of biological importance was supported by its low expression in cultured patients’ skin fibroblasts (Tosic et al., 2006) and by the decreased stimulation of the enzyme activity when challenged by oxidative stress (Gysin et al., 2007).”
BackgroundMethodResultInfluentialSelf-citationCecerska‐Heryć, E., Polikowska, A., Serwin, N. M., Michalczyk, A., Stodolak, P., Goszka, M., Zoń, M., Budkowska, M., Tyburski, E. M., Podwalski, P., et al. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.05.018 · Cited by 16
Kim, Q., Conus, P., & Cuénod, M. (2010) · Lifestyle Genomics · doi:10.1159/000324366 · Cited by 16
Self-citationNeurodegenerative Aspects in Vulnerability to Schizophrenia Spectrum Disorders
Archer, T., Ricci, S., Garcia, D., & Ricciardi, M. R. (2014) · Neurotoxicity Research · doi:10.1007/s12640-014-9473-0 · Cited by 17
“2009; Dringen and Hirrlinger 2003), and a GCL gene polymorphism, affecting GSH synthesis, is associated with the disorder (Tosic et al. 2006).”
BackgroundGlutamate cysteine ligase (GCL) and self reported depression: An association study from the HUNT
Berk, M., Johansson, S., Wray, N. R., Williams, L. J., Olsson, C. A., Haavik, J., & Bjerkeset, O. A. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.12.019 · Cited by 13
“The two SNPs (rs2301022 and rs3170633) from GCLM found to be associated with schizophrenia (Tosic et al., 2006) were selected for genotyping together with rs743110, a proxy for rs2301022 (r=0.”
BackgroundGould, R. L., Craig, S. W., McClatchy, S., Churchill, G. A., & Pazdro, R. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102093 · Cited by 11
Mokrane, N., Snabi, Y., Cens, T., Guiramand, J., Charnet, P., Bertaud, A., Ménard, C., Rousset, M., Ferreira, M. D. J., Thibaud, J., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.785727 · Cited by 11
Kashani, F. L., Kordi-Tamandani, D. M., Sahranavard, R., Hashemi, M. M., Tamandani, F. K., & Torkamanzehi, A. (2011) · Neuron Glia Biology · doi:10.1017/s1740925x12000130 · Cited by 9
Role of Redox Dysregulation in White Matter Anomalies Associated with Schizophrenia
Monin, A., Fournier, M., Baumann, P., Cuénod, M., & Kim, Q. (2015) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-800981-9.00028-6 · Cited by 12
Self-citationButticaz, C., Gysin, R., Cuénod, M., & Kim, Q. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.12.002 · Cited by 11
Self-citationBeneficial Upshots of Naturally Occurring Antioxidant Compounds against Neurological Disorders
Saha, S., Sadhukhan, P., & Sil, P. C. (2017) · Wiley eBooks · doi:10.1002/9783527803781.ch3 · Cited by 12
Shahzad, S., Batool, Z., Afzal, A., & Haider, S. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01090-6 · Cited by 8
Effects of GSTA1 and GPX3 Polymorphisms on the Risk of Schizophrenia in Chinese Han Population
Liu, C., Song, S., Zhang, J., Li, X., & Gao, H. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s236298 · Cited by 9
Carbonyl stress in schizophrenia
Itokawa, M., Miyashita, M., Arai, M., & Miyata, T. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140044 · Cited by 8
The coupling of low-level auditory dysfunction and oxidative stress in psychosis patients
Geiser, E., Retsa, C., Knebel, J., Ferrari, C., Jenni, R., Fournier, M., Alameda, L., Baumann, P., Clarke, S., Conus, P., et al. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.02.002 · Cited by 8
“…tissue (Do et al., 2000; Flatow et al., 2013; Gawryluk et al., 2011; see also Kim et al., 2016 for NAD+/NADH alterations) and are consistent with polymorphisms in key genes for GSH synthesis reported for schizophrenia (Gysin et al., 2007; Rodriguez-Santiago et al., 2010; Tosic et al., 2006).”
BackgroundUnstable genes unstable mind: Beyond the central dogma of molecular biology
Hegde, M. V., & Saraph, A. A. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.03.051 · Cited by 8
“The gene of the key GSH synthesizing enzyme, glutamate cysteine ligase, modifier (GCLM) subunit, has been shown to be strongly associated with schizophrenia in two case-control studies and in one family study [42].”
BackgroundDysregulation of Glutathione Synthesis in Psychiatric Disorders
Lorenc‐Koci, E. (2014) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-1-4939-0440-2_14 · Cited by 8
Oxidative stress in schizophrenia as a promising target for psychopharmacotherapy
Потанин, С. С., & Ma, M. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2021121091131 · Cited by 6
Dusi, N., Cecchetto, F., & Brambilla, P. (2014) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-1-4939-0440-2_9 · Cited by 6
Raffa, M., Jrad, B. B. H., Khelil, A. H., Kerkeni, A., & Mechri, A. (2016) · Gene Reports · doi:10.1016/j.genrep.2016.07.007 · Cited by 6
Barron, H., Hafizi, S., & Mizrahi, R. (2017) · Modern trends in psychiatry · doi:10.1159/000470810 · Cited by 8
Pilot Study on Schizophrenia in Sardinia
Ott, J., Macciardi, F. M., Shen, Y., Carta, M. G., Murru, A., Triunfo, R., Robledo, R., Rinaldi, A., Contu, L., & SINISCALCO, M. (2010) · Human Heredity · doi:10.1159/000313844 · Cited by 8
Self-citationNeurobiology of Schizophrenia Spectrum Disorders
Heckers, S. (2009) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v38n5p431 · Cited by 10
Oxidative Stress in Schizophrenia
Dietrich‐Muszalska, A. (2014) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-1-4939-0440-2_2 · Cited by 6
N-acetyl-cysteine in Schizophrenia: Potential Role on the Sensitive Cysteine Proteome
Martínez, M. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867326666191015091346 · Cited by 5
Increased Lymphocyte Caspase-3 Activity in Patients with Schizophrenia
Lazarevic, D. S., Đorđević, V. V., Ćosić, V., Vlahović, P., Tošić-Golubović, S., Ristić, T., & Đorđević, V. B. (2010) · Journal of Medical Biochemistry · doi:10.2478/v10011-011-0002-x · Cited by 5
“GCLM gene expression was decreased in patients’ fibroblasts (25).”
BackgroundHashimoto, K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.06.025 · Cited by 5
Can glutathione be a biomarker for suicide risk in women 18 months postpartum?
Schmidt, P. M. D. S., Trettim, J. P., Longoni, A., Grings, M., de Matos, M. B., Quevedo, L. D. Á., Ardais, A. P., Nedel, F., Ghisleni, G., Leipnitz, G., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1142608 · Cited by 6
Glutathione Deficit and Redox Dysregulation in Animal Models of Schizophrenia
Steullet, P., Cabungcal, J.-H., Kulak, A., Cuénod, M., Schenk, F., & Kim, Q. (2011) · Neuromethods · doi:10.1007/978-1-61779-157-4_7 · Cited by 4
Self-citationKulak, A. (2012) · Schizophrenia Research · doi:10.1016/s0920-9964(12)70162-7 · Cited by 4
Pavan, T., Steullet, P., Alemán‐Gómez, Y., Jenni, R., Schilliger, Z., Cleusix, M., Alameda, L., Kim, Q., Conus, P., Hagmann, P., et al. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103883 · Cited by 4
Đorđević, V. V., Jevtović−Stoimenov, T., Lazarevic, D. S., Stojanović, I. R., Trajanović, L., Žikić, O., & Đorđević, V. B. (2014) · Journal of Medical Biochemistry · doi:10.2478/jomb-2014-0023 · Cited by 3
Palm, D., Uzoni, A., Kronenberg, G., Thome, J., & Faltraco, F. (2023) · Pharmacopsychiatry · doi:10.1055/a-1147-1552 · Cited by 4
“Several studies report about reduced glutathione (GSH) synthesis in skin fibroblasts of SCZ subjects and altered proteome reaction in response to oxidative stress [70, 71].”
BackgroundPapel del estrés oxidativo en la esquizofrenia
Soto‐Bernardini, M. C., & Raventós, H. (2008) · Acta Médica Costarricense · doi:10.51481/amc.v50i4.3 · Cited by 11
Neurotoxic Vulnerability Underlying Schizophrenia Spectrum Disorders
Archer, T., Karilampi, U., Ricci, S., & Rapp‐Ricciardi, M. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_119 · Cited by 3
Pharmacogenomics and antipsychotics: efficacy and adverse drug reactions
Tsermpini, E. E., Terzi, T., Plesničar, B. K., & Dolžan, V. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-819602-1.00010-3 · Cited by 3
Schizophrenia Biomarkers: A Means to Advance Disease Understanding, Diagnosis and Treatment
Schwarz, E., & Bahn, S. (2008) · Springer eBooks · doi:10.1007/978-0-387-79251-4_4 · Cited by 2
Muratore, C. (2010) · Digital Repository Service (Northeastern University) · doi:10.17760/d20000269 · Cited by 3
Pour une réhabilitation de la notion de schizoïdie
Bovet, P. (2007) · PSN · doi:10.1007/s11836-007-0018-y · Cited by 1
“Des anomalies ont été récemment mises en évidence chez les schizophrènes sur des gènes contrôlant la synthèse du glutathion [28].”
Self-citationMitochondrial and metabolic abnormalities in neurodevelopmental disorders
Frye, R. E., & Rossignol, D. A. (2016) · Journal of Pediatric Biochemistry · doi:10.3233/jpb-120059 · Cited by 2
Che, R., Tang, W. D., Shao, L., Zhao, Q., Huang, K., Tang, R., Li, Z., Zhao, X., Ji, W., Zhou, G., et al. (2009) · Psychiatric Genetics · doi:10.1097/ypg.0b013e32832cec76 · Cited by 2
“A recent study reported that rs2301022 in GCLM was significantly associated with schizophrenia in the Danish population (Tosic et al., 2006) but did not confirm in the Japanese population (Matsuzawa et al.”
BackgroundResultInfluentialSpasic, D. M., Spasić, S. D., Nikolić‐Kokić, A., & Miljević, Č. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167105 · Cited by 1
“Functional GCLM/GCLC studies, early-psychosis MRS-genotype study, PRODH study, pathway PRS, large GWAS [18–23] A subset of liability may influence redox adaptation.”
Vladimir, V. H., Jevtovi, T., Stojanovi, I., & Trajanovi, L. (2014) · Cited by 1
Metadata
- Authors
- Tosic, M., Ott, J., Barral, S., Bovet, P., Deppen, P., Gheorghita, F., Matthey, M.-L., Parnas, J., Preisig, M., Saraga, M., Solida, A., Timm, S., Wang, A. G., Werge, T., Cuénod, M., & Quang Do, K.
- Affiliations
- Rockefeller University (US)
- Centre Hospitalier Universitaire Vaudois (CH)
- Hvidovre Hospital (DK)
- Frederiksberg Hospital (DK)
- Amager Hospital (DK)
- Sankt Hans Hospital (DK)
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2006-09
- Volume
- 79
- Issue
- 3
- Pages
- 586-592
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1559555
- OpenAlex
- W2039366241
- Cited by
- 234
- References
- 43
- Citations by year
- 2026: 6 · 2025: 2 · 2024: 6 · 2023: 12 · 2022: 5 · 2021: 10 · 2020: 6 · 2019: 9 · 2018: 6 · 2017: 16 · 2016: 12 · 2015: 8 · 2014: 21 · 2013: 10 · 2012: 15
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2513 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (R01MH044292, MH 44292, R37MH044292)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Keywords
- schizophrenia, oxidative stress, GCLM, glutathione metabolism, glutathione, genetic susceptibility, redox regulation, cerebrospinal fluid, prefrontal cortex, fibroblast gene expression
- MeSH terms
- Fibroblasts, Glutamate-Cysteine Ligase, Gene Frequency, Glutathione, Humans, RNA, Messenger, Schizophrenia, Down-Regulation, Case-Control Studies, Oxidative Stress, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.